Investment, research focus, and competition are shifting across pharma as companies refine strategies that respond to scientific progress and market pressure. This edition brings those movements into clearer view, guided by one idea: leadership that adapts with purpose.

The opening feature, Women in Pharma Awards 2026 opens entries to recognise industry leaders, points to how talent development and leadership visibility influence long-term resilience.

Recognition programmes signal that organisations are reassessing how capability, diversity, and accountability shape performance. Keenova completes spinout of Par Health and rebrands from Mallinckrodt adds a view of restructuring that reflects broader trends in portfolio management and capital discipline.

Businesses are seeking sharper clinical focus and operational clarity, responding to regulatory scrutiny and investor expectation. Novo Nordisk India launches Poviztra with Emcure Pharma shows how established players continue to strengthen therapeutic pipelines through targeted partnerships that expand reach and delivery capacity.

These stories mark a period defined by strategic recalibration, closer collaboration, and an appetite for models that support sustainable growth. See how each development contributes to a sector moving with intent, supported by innovation and steady investment in capability.